CD274 and glioblastoma: TTFields therapy is approved for treatment of patients with recurrent glioblastoma (GBM), newly-diagnosed GBM (concurrent with maintenance temozolomide), unresectable, locally advanced or metastatic pleural mesothelioma (concomitant with pemetrexed and a platinum-based agent), and metastatic non-small cell lung cancer (NSCLC; together with PD-1/PD-L1 inhibitors or docetaxel) following progression on or after platinum based chemotherapy [1–3].